We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Apparatus Mimics the Human Digestive System for Oral Drug Studies

By LabMedica International staff writers
Posted on 15 Apr 2014
Image: Diagram of the apparatus for testing drug solubility (Photo courtesy of the University of Huddersfield).
Image: Diagram of the apparatus for testing drug solubility (Photo courtesy of the University of Huddersfield).
A team of British drug developers has created an instrument that mimics the human digestive system, which will allow them to accurately determine how orally-administered medications are dissolved and then absorbed.

Investigators at the University of Huddersfield (United Kingdom) sought a way to study the behavior of oral drugs in the digestive tract that would avoid the differences between the digestive systems of humans and laboratory animals.

To this end, they developed an apparatus for testing drug solubility that included a chamber for holding a solvent medium —often a bicarbonate based buffer system—as well as a pH probe connected to tanks of carbon dioxide and helium.

The heart of the apparatus was the control unit that monitored changes in pH of the solvent medium and, as appropriate, fed pH increasing and/or pH reducing gas from the tanks into the chamber. The control unit was able to maintain a uniform pH during testing or could be set to provide a dynamically adjustable pH range, for example to three or more different pH levels in order to test the performance of a drug carrier at different levels of acidity or alkalinity.

“By minimizing human trials we would reduce the cost of development, which is then charged to patients when the drug comes to the market—if the development costs are lower, then we can make new drugs more affordable,” said Dr. Hamid Merchant, senior lecturer of pharmaceutics at the University of Huddersfield.

Related Links:

University of Huddersfield


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
Automated Clinical Chemistry Analyzer
Envoy 500+

Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
INTEGRA BIOSCIENCES AG